The risks of 4 types of skin cancers were investigated among patients who have neurofibromatosis type 1, a multisystem autosomal dominant genetic syndrome characterized by loss of neurofibromin. Basal ...

Neurofibromatosis type 1 (NF1) is a genetic condition that causes tumors to grow along nerves in the skin, brain, and other parts of the body. These tumors are usually noncancerous (benign), but they ...

Other than surgery and medications, including opioids, there are few options for treating pain symptoms, which affect more than half of all patients with neurofibromatosis type 1. Researchers recently ...

Sequences of 529 cancer driver genes were analyzed in 6,381 tumors, yielding 391 NF1-mutated tumors in which NF1 LOH analysis was performed. Driver genes were evaluated by tumor type including ...

Neurofibromatosis type 1 (NF1) is a hereditary condition arising from mutations in the NF1 gene, which encodes neurofibromin—a key regulator of cellular signalling and neural development. Children ...

Neurofibromatosis type 1 (NF1) is a genetically inherited disorder that manifests in a broad spectrum of clinical features including dermatological, neurological, skeletal and notably, ocular ...

GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...

Scientists from the National Cancer Institute’s (NCI) Center for Cancer Research, and the Washington University School of Medicine in St. Louis have developed a blood test that, they believe, could ...

Although brain tumors have largely remained resistant to immunotherapy, a new study has shown that a slow-growing brain tumor arising in patients affected by neurofibromatosis type 1 (NF1) may be ...

New research shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis type 1, or NF1, the ...

What Is Koselugo, and Why Does It Matter? Koselugo (selumetinib) is an oral medicine that helps slow the growth of certain tumors. The FDA has approved it for adults with neurofibromatosis type 1 (NF1 ...

Inactivating germ line mutations in the neurofibromatosis type 1 (NF1) gene are responsible for the many manifestations of this disease that range from intellectual deficits, to autism, to bone ...